Fri, Dec 19, 2014, 12:10 AM EST - U.S. Markets open in 9 hrs 20 mins


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Feb 10, 2011 9:35 PM Flag

    MYGN's prostate CA prognosis test:

    Myriad Genetics announces that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS molecular diagnostic test significantly predicts prostate cancer outcome (18.95 +0.52)
    The study demonstrated that a patient's cell cycle progression score is a strong indicator of the risk of disease recurrence and death in patients diagnosed with prostate cancer and may play an essential role in determining the appropriate treatment for patients with prostate cancer. The study will appear in an article, entitled "Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study."

    It would be interesting to see what of these 46 variants respond to clusterin inhibition. Also, even better would be if most of them would ONLY be inhibited with a clusterin inhibitor. t

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.28+0.050(+2.24%)Dec 18 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.